Does Rallies show Form 4 insider transactions for MRNA?

Yes. Rallies tracks MRNA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MRNA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MRNA. It does not provide personalized investment advice.

MRNA (Moderna) Stock Analysis - Insider Trades

Moderna (MRNA) is a publicly traded Healthcare sector company. As of May 20, 2026, MRNA trades at $48.15 with a market cap of $19.09B and a P/E ratio of -5.92. MRNA moved +5.33% today. Year to date, MRNA is +49.58%; over the trailing twelve months it is +71.92%. Its 52-week range spans $22.28 to $67.96. Analyst consensus is neutral with an average price target of $44.73. Rallies surfaces MRNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MRNA stock inside the company?

Recent MRNA insider activity includes Hoge Stephen sold 53.34K, Hussain Abbas sold 5.68K, Klinger Shannon Thyme sold 13.88K, Hoge Stephen sold 160.01K, and AFEYAN NOUBAR sold 23.85K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MRNA Key Metrics

Key financial metrics for MRNA
Metric	Value
Price	$48.15
Market Cap	$19.09B
P/E Ratio	-5.92
EPS	$-8.15
Dividend Yield	0.00%
52-Week High	$67.96
52-Week Low	$22.28
Volume	3.87M
Avg Volume	0
Revenue (TTM)	$2.23B
Net Income	$-3.19B
Gross Margin	22.11%

Recent MRNA Insider Trades

Hoge Stephen sold 53.34K (~$2.58M) on May 15, 2026.
Hussain Abbas sold 5.68K (~$264.95K) on May 1, 2026.
Klinger Shannon Thyme sold 13.88K (~$726.05K) on Mar 2, 2026.
Hoge Stephen sold 160.01K (~$7.81M) on Feb 23, 2026.
AFEYAN NOUBAR sold 23.85K (~$703.31K) on Dec 11, 2025.

Latest MRNA News

Moderna Underweight with $40 December 2026 Price Target — May 20, 2026
Moderna Shares Rally 13% as Hantavirus Outbreak Spurs Preclinical mRNA Efforts — May 16, 2026
Moderna Named No.1 Impactful Company, Gains EU Approval for mCOMBRIAX® and Expands Partnerships — May 12, 2026
Moderna Launches Preclinical Hantavirus Vaccine Research, Shares Surge — May 11, 2026
Moderna Outperform Rating After 26.6% Flu Vaccine Efficacy and Hantavirus Success — May 8, 2026

MRNA Analyst Consensus

15 analysts cover MRNA: 0 strong buy, 1 buy, 13 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $44.73.

Common questions about MRNA

Who is trading MRNA stock inside the company?: Recent MRNA insider activity includes Hoge Stephen sold 53.34K, Hussain Abbas sold 5.68K, Klinger Shannon Thyme sold 13.88K, Hoge Stephen sold 160.01K, and AFEYAN NOUBAR sold 23.85K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MRNA?: Yes. Rallies tracks MRNA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MRNA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MRNA. It does not provide personalized investment advice.